<DOC>
	<DOCNO>NCT01121822</DOCNO>
	<brief_summary>The aim study evaluate new formulation influenza vaccine 2010-2011 Northern Hemisphere ( NH ) season term immunogenicity safety correspond population check compliance Committee Proprietary Medicinal Products ( CPMP ) Note Guidance ( NfG ) CPMP/BWP/214/96 Objectives : - To evaluate compliance , term immunogenicity , influenza vaccine ( split virion , inactivate ) NH 2010-2011 formulation requirement Committee Proprietary Medicinal Products ( CPMP ) Note Guidance ( NfG ) CPMP/BWP/214/96 age group - To describe safety influenza vaccine ( split virion , inactivate ) NH 2010-2011 formulation age group</brief_summary>
	<brief_title>Immunogenicity Safety Vaccine Against Influenza ( 2010-2011 Northern Hemisphere Season , Intramuscular Route )</brief_title>
	<detailed_description>Each participant receive dose vaccine Day 0 follow 21 day post-vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination Entitled national social security . Exclusion Criteria : Febrile illness ( temperature ≥ 38.0°C ) moderate severe acute illness/infection ( accord investigator judgment ) day vaccination Known systemic hypersensitivity egg , chicken protein , neomycin , formaldehyde octoxynol9 , vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Known pregnancy , positive urine pregnancy test Currently breastfeed child History pandemic H1N1 influenza vaccination History clinically laboratory confirm pandemic H1N1 influenza infection History influenza vaccination within previous 6 month ( pandemic H1N1 influenza vaccine ) Receipt adjuvanted influenza vaccine clinical trial within previous 12 month Known suspected congenital acquire immunodeficiency , result example : Endstage renal disease require dialysis Active neoplastic disease active hematologic malignancy Receipt immunosuppressive therapy immunemodifying drug , limit : anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C Receipt blood bloodderived product past 3 month , might interfere assessment immune response Chronic illness , opinion investigator , stage might interfere trial conduct completion History thrombocytopenia , contraindicate intramuscular ( IM ) vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine 3 week follow trial vaccination Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Influenza virus</keyword>
	<keyword>Intramuscular</keyword>
</DOC>